labuxtinib   Click here for help

GtoPdb Ligand ID: 12870

Synonyms: Compound 1 [WO2022109595] | example F91 [WO2013033070] | THB-335 | THB335
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The structure for labuxtinib was obtained from proposed INN list 129 (August 2023) where it is described as a tyrosine kinase inhibitor and antineoplastic agent. Patent information suggests that it is a KIT inhibitor [1-2]. It is most likely that labuxtinib is the INN for Third Harmonic Bio's candidate KIT inhibitor THB335. Development of the initial clinical lead THB001 was discontinued in late 2022 when hepatotoxicity was observed in a phase 1b study. THB335 is a follow-up molecule with structural modifications to address the toxicity risk, and is still in active development. As of January 2025 no structures have been formally declared for either of these inhibitors.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

labuxtinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 78.65
Molecular weight 377.37
XLogP 1.6
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1=CC=C(C=C1NC(=O)C2=CN=C3C=CC=CN23)C4=NOC(=N4)[C@H]5C[C@@H]5F
Isomeric SMILES F[C@@H]1[C@H](C1)C2=NC(=NO2)C=3C=CC(=C(C3)NC(=O)C4=CN=C5N4C=CC=C5)C
InChI InChI=1S/C20H16FN5O2/c1-11-5-6-12(18-24-20(28-25-18)13-9-14(13)21)8-15(11)23-19(27)16-10-22-17-4-2-3-7-26(16)17/h2-8,10,13-14H,9H2,1H3,(H,23,27)/t13-,14-/m0/s1
InChI Key RHNJOZCVGSBEAG-KBPBESRZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
THB335 is proposed for potential to treat mast cell-mediated inflammatory diseases. Progression to phase 2 for chronic spontaneous urticaria is planned (scheduled to begin in mid-2025).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06425861 A First in Human Trial Evaluating THB335 in Healthy Participants Phase 1 Interventional Third Harmonic Bio, Inc.